Drug profile · INN
candesartan cilexetil
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
candesartan cilexetil (CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE) is a type-1 angiotensin ii receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — candesartan cilexetil
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 7
- Data quality
- 0.89
Quick answer
candesartan cilexetil (CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE) is a type-1 angiotensin ii receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Type-1 angiotensin II receptor antagonist
Primary target: Type-1 angiotensin II receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is candesartan cilexetil?
candesartan cilexetil (CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE) is a type-1 angiotensin ii receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for candesartan cilexetil?
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE is a marketed brand name for candesartan cilexetil. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of candesartan cilexetil?
candesartan cilexetil has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.